Anika Therapeutics (ANIK) Tops Q1 EPS by 45c ; Offers Guidance
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $15.36 +1.19%
Revenue Growth %: +3.5%
Financial Fact:
Cost of product revenue: 5M
Today's EPS Names:
CRMT, More
Revenue Growth %: +3.5%
Financial Fact:
Cost of product revenue: 5M
Today's EPS Names:
CRMT, More
Join SI Premium – FREE
Anika Therapeutics (NASDAQ: ANIK) reported Q1 EPS of $0.27, $0.45 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $29.6 million versus the consensus estimate of $28.11 million.
GUIDANCE:
Anika Therapeutics sees FY2026 revenue of $114-122.5 million, versus the consensus of $117.2 million.
For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump said he was unaware of his earnings from crypto
- Trifecta Gold closes $1.66M private placement for Yukon exploration
- Raymond James Upgrades Aecon Group (ARE:CN) (AEGXF) to Outperform
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
